A digital mindfulness-based intervention (MBI) tool lowers anxiety, depression and perceived stress among patients with non-infectious uveitis (NIU), research published in Ophthalmology suggests.
Few studies have assessed whether mental health interventions benefit patients with ocular conditions, and this study, The Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases (MARiGOLD) Trial (ClinicalTrials.gov: NCT06585670), is the first to assess how a digital MBI affects patients with uveitis, which is often accompanied by anxiety, depression, and increased stress.
Researchers at the F.I. Proctor Foundation Uveitis Clinic at the University of California, San Francisco, recruited 100 adults (mostly women) with NIU seen at its clinics and assigned them to either receive immediate access with Calm Health, a digital MBI smartphone mobile application that provides guided meditation and mindfulness sessions, or be put on a waitlist. The patients exhibited at least 5 points on the General Anxiety Disorder-7 (GAD-7) or the Patient Health Questionnaire-9 (PHQ-9) surveys at the beginning of the study.
The investigators asked patients in the intervention group to use Calm Health for at least 10 minutes daily for 8 weeks, while control individuals did not receive a new mindfulness intervention. The median app use during the study for the intervention group was 579 minutes (quartile 1397.79; quartile 3923.00), according to the researchers.
The results of this study suggest that MBIs may be a valuable tool to incorporate into NIU care, especially in settings where access to traditional mental health services is limited.
After adjusting for baseline GAD-7 scores, the investigators found that GAD-7 scores at 8 weeks were lower in the Calm Health group than in the waitlist group (mean difference, -1.7 points; 95% confidence interval [CI], -3.17 to -0.23). PHQ-9 scores were 1.9 points lower (95% CI, -3.04 vs -0.76) and Perceived Stress Scale-10 scores were 3.69 points lower (95% CI, -6.00 vs -1.37) in the Calm Health group than in the waitlist group.
National Eye Institute Visual Function Questionnaire-25 scores were similar between groups (P =.18). More app time was not linked with GAD-7 score at study endpoint.
According to the surveys, the leading challenges impacting patients’ mental health were vision loss, ocular pain or discomfort, and medication side effects. Seven participants (10 instances) reported experiencing suicidal ideation.
“The results of this study suggest that MBIs may be a valuable tool to incorporate into NIU care, especially in settings where access to traditional mental health services is limited,” the researchers explain.
The investigators explained that the intervention’s self-directed, app-based format increases its accessibility and affordability.
Study limitations include use of wait-list control design and 1 center.
Disclosure: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.